PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Product offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Classification
• Mode of transmission
• Epidemiology
• Diagnosis
• Symptoms
• Treatment
PART 06: Key marketed drugs
• Hepatitis A
• Hepatitis B
• Hepatitis C
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type
• Hepatitis A
• Hepatitis B
• Hepatitis C
PART 09: Market segmentation by MOA
• Virus-specific agents
• Non-specific agents
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
• Competitive scenario
• Gilead Sciences
• Johnson & Johnson
• F. Hoffman-La Roche
• Merck
• GlaxoSmithKline
• Vertex Pharmaceuticals
• Novartis
• Other prominent vendors
PART 17: Key vendor analysis
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Roche
• Vertex Pharmaceuticals
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
[List of Exhibits]
Exhibit 01: Mode of transmission and incubation period of different types of hepatitis
Exhibit 02: Risk factors for hepatitis A transmission
Exhibit 03: Risk factors for hepatitis B transmission
Exhibit 04: Risk factors for hepatitis C transmission
Exhibit 05: Worldwide endemicity of HAV infection
Exhibit 06: Endemicity pattern of HBV worldwide
Exhibit 07: Prevalence of HBV in APAC
Exhibit 08: Acute hepatitis B infection by age group 2005-2013
Exhibit 09: Prevalence of hepatitis B in US 2005-2013
Exhibit 10: Estimated HBV incidence rates in APAC countries 2004
Exhibit 11: Prevalence rates of hepatitis C across different regions 2012
Exhibit 12: Antibodies indicating different hepatitis types
Exhibit 13: Tests for viral proteins and generic materials
Exhibit 14: Screening tests for hepatitis B infection
Exhibit 15: Screening tests for hepatitis C infection
Exhibit 16: Types of hepatitis and symptoms
Exhibit 17: Recommended dosages and schedules for hepatitis A vaccines
Exhibit 18: Recommended dosages and schedules for hepatitis B vaccines
Exhibit 19: Combination vaccines for hepatitis A and/or hepatitis B
Exhibit 20: Hepatitis A: Key marketed vaccines
Exhibit 21: Hepatitis B: Key marketed drugs
Exhibit 22: Hepatitis C: Key marketed drugs
Exhibit 23: Global hepatitis drugs market 2014-2019 ($ billions)
Exhibit 24: Five forces analysis
Exhibit 25: Market segmentation by type
Exhibit 26: Global hepatitis A drugs market 2014-2019 ($ billions)
Exhibit 27: Global hepatitis B drugs market 2014-2019 ($ billions)
Exhibit 28: Global hepatitis C drugs market 2014-2019 ($ billions)
Exhibit 29: Snapshot of global hepatitis drugs market
Exhibit 30: Classification of global hepatitis drugs market by MOA
Exhibit 31: Global hepatitis drugs market by geographical segmentation 2014
Exhibit 32: List of key drivers
Exhibit 33: List of key challenges
Exhibit 34: Impact of drivers and challenges
Exhibit 35: List of key trends
Exhibit 36: Gilead: Pipeline candidates for hepatitis B
Exhibit 37: Gilead Sciences: Pipeline candidates for hepatitis C
Exhibit 38: Gilead Sciences: Key takeaways
Exhibit 39: Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
Exhibit 40: Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
Exhibit 41: Johnson & Johnson: Key takeaways
Exhibit 42: Roche: Pipeline candidates for hepatitis C
Exhibit 43: F. Hoffman-La Roche: Key takeaways
Exhibit 44: Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
Exhibit 45: Merck: Pipeline candidates for hepatitis C
Exhibit 46: Merck: Key takeaways
Exhibit 47: GlaxoSmithKline: Pipeline candidates for hepatitis B
Exhibit 48: GlaxoSmithKline: Pipeline candidates for hepatitis C
Exhibit 49: GlaxoSmithKline: Key takeaways
Exhibit 50: Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
Exhibit 51: Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
Exhibit 52: Vertex Pharmaceuticals: Key takeaways
Exhibit 53: Novartis: Key takeaways
Exhibit 54: Gilead Sciences: List of key drugs
Exhibit 55: GlaxoSmithKline: Segmentation by product 2014
Exhibit 56: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 57: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: Johnson & Johnson: Business segmentation
Exhibit 59: Johnson & Johnson: Key products of medical devices segment
Exhibit 60: Johnson & Johnson: Medical devices segmentation by revenue 2014
Exhibit 61: Merck: Business segmentation
Exhibit 62: Merck: Geographical segmentation
Exhibit 63: Business segmentation by revenue
Exhibit 64: Novartis: Business segmentation
Exhibit 65: Novartis: Geographical segmentation
Exhibit 66: Novartis: Business segmentation by revenue
Exhibit 67: Roche: Business segments
Exhibit 68: Roche: Pharmaceuticals segmentation
Exhibit 69: Roche: Revenue comparison by business segment
Exhibit 70: Roche: Geographical segmentation
Exhibit 71: Vertex Pharmaceuticals: Product segmentation by revenue
Exhibit 72: Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 73: Vertex Pharmaceuticals: Geographical segmentation
【掲載企業】
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Mitsubishi Tanabe Pharma
【資料のキーワード】
A型肝炎、B型肝炎、C型肝炎、肝炎治療薬、医薬品
【調査方法】
一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)